THE RATE OF EMERGENCE OF AUTOANTIBODIES IS STABLE BETWEEN 6 MONTHS AND AT LEAST 8 YEARS OF AGE BUT DEPENDS ON HLA-CONFERRED RISK IN A PROSPECTIVELY FOLLOWED-UP POPULATION-BASED BIRTH COHORT
スポンサーリンク
概要
- 論文の詳細を見る
- 2005-10-01
著者
-
Nanto-salonen Kirsti
Jdrf Center For Prevention Of Type 1 Diabetes In Finland At The Universities Of Turku
-
Knip Mikael
Jdrf Center For Prevention Of Type 1 Diabetes In Finland At The Universities Of Turku
-
Knip Mikael
University Of Helsinki
-
Ilonen Jorma
Jdrf Center For Prevention Of Type 1 Diabetes In Finland At The Universities Of Turku
-
Ilonen Jorma
Turku Immunology Centre And Department Of Virology University Of Turku
-
Simell Olli
Jdrf Center For Prevention Of Type 1 Diabetes In Finland At The Universities Of Turku
-
Simell Satu
Jdrf Center For Prevention Of Type 1 Diabetes In Finland At The Universities Of Turku
-
Simell Tuula
Jdrf Center For Prevention Of Type 1 Diabetes In Finland At The Universities Of Turku
-
HYOTY Heikki
JDRF Center for the Prevention of Type 1 Diabetes in Finland
-
ILONEN Jorma
University of Turku
-
HEKKALA Anne
JDRF Center for Prevention of Type 1 Diabetes in Finland at the Universities of Turku
-
SILEN Paivi
JDRF Center for Prevention of Type 1 Diabetes in Finland at the Universities of Turku
-
ILOLA Anna-Marja
JDRF Center for Prevention of Type 1 Diabetes in Finland at the Universities of Turku
-
LAHDE Jyrki
JDRF Center for Prevention of Type 1 Diabetes in Finland at the Universities of Turku
-
Hyoty Heikki
Jdrf Center For Prevention Of Type 1 Diabetes In Finland At The Universities Of Turku
-
Knip Mikael
Jdrf Center For The Prevention Of Type 1 Diabetes In Finland
-
HYOTY Heikki
Department of Virology, Medical School, University of Tampere
関連論文
- MATERNAL ENTEROVIRUS ANTIBODIES IN BREAST MILK PROTECT THE CHILD FROM ENTEROVIRUS INFECTIONS-RESULTS FROM THE TRIGR (PILOT 2) TRIAL
- DIETARY INSULIN AS AN IMMUNOGEN AND TOLEROGEN
- FEASIBILITY OF A PLACEBO-CONTROLLED DOUBLE-BLINDED TYPE 1 DIABETES (T1D) PREVENTION TRIAL TESTING EFFICACY OF NASAL INSULIN IN A POPULATION-BASED COHORT OF CHILDREN WITH HLA-CONFERRED T1D RISK AND MULTIPLE AUTOANTIBODIES
- ENTEROVIRUS ANALYSES FROM PANCREATIC TISSUE OF A CHILD POSITIVE FOR DIABETES-ASSOCIATED AUTOANTIBODIES
- ANALYSIS OF REGULATORY CD4^+CD25^ T-CELLS AND NATURAL KILLER T-CELLS IN CHILDREN WITH NEWLY DIAGNOSED TYPE 1 DIABETES AND IN AUTOANTIBODY-POSITIVE SUBJECTS
- PTPN22 LYMPHOID TYROSINE PHOSPHATASE Arg620Trp VARIANT REGULATES INSULIN AUTOIMMUNITY AND PROGRESSION TO TYPE 1 DIABETES
- ENHANCED T-CELL REACTIVITY TO INSULIN PEPTIDE A1-12 IN CHILDREN WITH RECENTLY DIAGNOSED TYPE 1 DIABETES OR DIABETES ASSOCIATED AUTOANTIBODIES
- TEMPORAL SEASONALITY IN EMERGENCE OF DIABETES-ASSOCIATED AUTOANTIBODIES IN CHILDREN
- THE RATE OF EMERGENCE OF AUTOANTIBODIES IS STABLE BETWEEN 6 MONTHS AND AT LEAST 8 YEARS OF AGE BUT DEPENDS ON HLA-CONFERRED RISK IN A PROSPECTIVELY FOLLOWED-UP POPULATION-BASED BIRTH COHORT
- MOLECULAR ANALYSIS OF AN ECHOVIRUS 3 STRAIN ISOLATED FROM AN INDIVIDUAL WHO SUBSEQUENTLY EXHIBITED DIABETES-ASSOCIATED AUTOIMMUNITY
- DECREASED in vitro TYPE 1 IMMUNE RESPONSE AGAINST COXSACKIE VIRUS B4 IN CHILDREN WITH TYPE 1 DIABETES
- PROBIOTICS FOR THE PREVENTION OF BETA-CELL AUTOIMMUNITY IN CHILDREN AT GENETIC RISK OF TYPE 1 DIABETES - PRODIA STUDY
- Expression of Toll-like Receptors in the Pancreas of Recent-onset Fulminant Type 1 Diabetes